Point: Treating stage II colon cancer: The quest for personalized adjuvant care

Maxwell T. Vergo, Al B Benson III*

*Corresponding author for this work

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

The development of treatment decision strategies to guide the use of adjuvant chemotherapy in patients with stage II colon cancer continues to challenge many oncologists. Clearly, recurrence risk and prognosis for patients with stage II colon cancer can be variable, with subsets of patients with stage II disease at potentially higher risk than some with stage III. Adjuvant chemotherapy seems to produce a consistent relative risk reduction for recurrence across studies. Using clinical calculators to predict individual recurrence risk based on histopathologic and patient data allows this relative risk reduction to be translated into absolute benefit to the patient. In addition, gene expression assays in combination with these histopathologic data may further improve the accuracy of recurrence risk calculations and allow more accurate absolute benefit estimations. This absolute benefit should be discussed with the patient, taking into account the risk of morbidity from chemotherapy and individual preferences to arrive at a shared medical decision regarding adjuvant chemotherapy.

Original languageEnglish (US)
Pages (from-to)1370-1374
Number of pages5
JournalJNCCN Journal of the National Comprehensive Cancer Network
Volume10
Issue number11
DOIs
StatePublished - Nov 1 2012

Fingerprint

Colonic Neoplasms
Adjuvant Chemotherapy
Recurrence
Risk Reduction Behavior
Morbidity
Gene Expression
Drug Therapy

ASJC Scopus subject areas

  • Oncology

Cite this

@article{da191fd0346f4a9894655133bce949ec,
title = "Point: Treating stage II colon cancer: The quest for personalized adjuvant care",
abstract = "The development of treatment decision strategies to guide the use of adjuvant chemotherapy in patients with stage II colon cancer continues to challenge many oncologists. Clearly, recurrence risk and prognosis for patients with stage II colon cancer can be variable, with subsets of patients with stage II disease at potentially higher risk than some with stage III. Adjuvant chemotherapy seems to produce a consistent relative risk reduction for recurrence across studies. Using clinical calculators to predict individual recurrence risk based on histopathologic and patient data allows this relative risk reduction to be translated into absolute benefit to the patient. In addition, gene expression assays in combination with these histopathologic data may further improve the accuracy of recurrence risk calculations and allow more accurate absolute benefit estimations. This absolute benefit should be discussed with the patient, taking into account the risk of morbidity from chemotherapy and individual preferences to arrive at a shared medical decision regarding adjuvant chemotherapy.",
author = "Vergo, {Maxwell T.} and {Benson III}, {Al B}",
year = "2012",
month = "11",
day = "1",
doi = "10.6004/jnccn.2012.0142",
language = "English (US)",
volume = "10",
pages = "1370--1374",
journal = "Journal of the National Comprehensive Cancer Network : JNCCN",
issn = "1540-1405",
publisher = "Cold Spring Publishing LLC",
number = "11",

}

Point : Treating stage II colon cancer: The quest for personalized adjuvant care. / Vergo, Maxwell T.; Benson III, Al B.

In: JNCCN Journal of the National Comprehensive Cancer Network, Vol. 10, No. 11, 01.11.2012, p. 1370-1374.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Point

T2 - Treating stage II colon cancer: The quest for personalized adjuvant care

AU - Vergo, Maxwell T.

AU - Benson III, Al B

PY - 2012/11/1

Y1 - 2012/11/1

N2 - The development of treatment decision strategies to guide the use of adjuvant chemotherapy in patients with stage II colon cancer continues to challenge many oncologists. Clearly, recurrence risk and prognosis for patients with stage II colon cancer can be variable, with subsets of patients with stage II disease at potentially higher risk than some with stage III. Adjuvant chemotherapy seems to produce a consistent relative risk reduction for recurrence across studies. Using clinical calculators to predict individual recurrence risk based on histopathologic and patient data allows this relative risk reduction to be translated into absolute benefit to the patient. In addition, gene expression assays in combination with these histopathologic data may further improve the accuracy of recurrence risk calculations and allow more accurate absolute benefit estimations. This absolute benefit should be discussed with the patient, taking into account the risk of morbidity from chemotherapy and individual preferences to arrive at a shared medical decision regarding adjuvant chemotherapy.

AB - The development of treatment decision strategies to guide the use of adjuvant chemotherapy in patients with stage II colon cancer continues to challenge many oncologists. Clearly, recurrence risk and prognosis for patients with stage II colon cancer can be variable, with subsets of patients with stage II disease at potentially higher risk than some with stage III. Adjuvant chemotherapy seems to produce a consistent relative risk reduction for recurrence across studies. Using clinical calculators to predict individual recurrence risk based on histopathologic and patient data allows this relative risk reduction to be translated into absolute benefit to the patient. In addition, gene expression assays in combination with these histopathologic data may further improve the accuracy of recurrence risk calculations and allow more accurate absolute benefit estimations. This absolute benefit should be discussed with the patient, taking into account the risk of morbidity from chemotherapy and individual preferences to arrive at a shared medical decision regarding adjuvant chemotherapy.

UR - http://www.scopus.com/inward/record.url?scp=84871404487&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84871404487&partnerID=8YFLogxK

U2 - 10.6004/jnccn.2012.0142

DO - 10.6004/jnccn.2012.0142

M3 - Article

C2 - 23138165

AN - SCOPUS:84871404487

VL - 10

SP - 1370

EP - 1374

JO - Journal of the National Comprehensive Cancer Network : JNCCN

JF - Journal of the National Comprehensive Cancer Network : JNCCN

SN - 1540-1405

IS - 11

ER -